Keywords: update, via-2291, ongoing, ph, ii, program, via

Update on VIA-2291 ongoing Ph II Program

Article | 14 April 2008

VIA Pharmaceuticals , a US biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, says that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

FDG

Fludeoxyglucose F 18 Injection

Go to drug listing